Dr.Shruti Bhat, an Expert in Pharmaceutical industry, brings to you some highlights from current pharma and clinical research news, views and data.
A technology designed to help deliver active ingredients has been reformulated by BASF to fit the regulations of the Japanese ‘quasi-drug’ market. The company refers to Cytovector as an intelligent penetration technology and said it can help the delivery of active ingredients due its positive charge, which improves the ingredients’ affinity with the cell membrane.
According to BASF, it can be particularly useful for formulations aiming to fight against wrinkle formation or whitening products.
The new reformulated Cytovector, Cytovector QD, can help formulators open up the Japanese whitening market, according to BASF, where there are significant growth opportunities.
Japan holds big potential for skin whitening
Skin whitening and brightening products find their main market in Japan, China and South Korea, and to a lesser extent India.
However, the sector is expanding with ingredients being formulated into a number of anti-aging products in the attempt to reduce the appearance of age spots and irregular pigmentation which can be associated with aging skin.
Cosmetochem launch novel Liposome Herbasec® range
Liposome Herbasec® is a novel range of standardized, liposomal-based botanical extracts in powder form. In Japan, skin whitening products come under the quasi drug regulation, which means their ingredients must be compliant with the Japanese Standard of Quasi-Drug Ingredients (JSQI) which is controlled by the Ministry of Health and Labor.
In order to fit the JSQI regulations, BASF had to remove one of the ingredients, the quaternized soy protein, and replace it with an ingredient listed with the JSQI of similar efficacy, BASF spokesperson Olivier Teillac explained.
In addition, Teillac explained that the encapsulated active ingredients associated with Cytovector QD must also be QD compliant with the JSQI if they are to be suitable for the Japanese market.
New Drugs Discovered to Fight Deadly Parasite
Scientists have discovered new drugs against a parasite that infects 50,000 to 70,000 people annually in Sub-Saharan Africa. About 30,000 of those infected die. A person gets it from being bitten by a tsetse (Tet-see) fly infected with the parasite. It causes human African trypanosomiasis (HAT) and can go the individual’s brain and disturb his or her sleep cycle. The disease is often referred to as Sleeping Sickness.
There are two drugs currently available. Melarsoprol is potentially fatal to the person being treated and eflornithine is expensive and requires staying in the hospital for a long time and the parasite is becoming resistance to it.
Most individuals who are infected are poor and cannot afford to be treated. In turn, pharmaceutical companies have little to no incentive to research and develop new drugs. This discovery was made by researchers at universities in Australia and Toronto.
Researchers are working on narrowing down the list to the drug or drugs, all taken by mouth, that can best treat the disease.
Researchers Aim To Speed Cancer Drug Development By Testing On Humans, Mice In Tandem.
The Boston Globe reported that "in the new work, funded with a $4.2 million economic stimulus grant from the National Cancer Institute, mice are receiving treatment in tandem with humans...to speed up and streamline the development of cancer drugs." Cheryl Marks, associate director in the division of cancer biology at the NCI, noted that "there are 800-plus drugs in the pharmaceutical pipeline, and we already don't have enough people going into clinical trials to begin with." But, because "mice can be engineered to carry one or more faulty genes known to cause human cancers," researchers are now inserting "various human prostate- and lung-cancer gene mutations...into mice," with the hope that "the mice, with simpler genetics than the humans, will reveal more about what is happening in the patients."
http://www.pharm-education.com/2010/04/technology-designed-to-help-deliver.html
Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
Http://www.drshrutibhat.com
Expert at leading Pharmaceutical R&D.
Translates innovative concepts to PROFITS.
TouTube Channel : Http://www.youtube.com/user/ShrutiBhat10
Do you have questions for the author?
A technology designed to help deliver active ingredients has been reformulated by BASF to fit the regulations of the Japanese ‘quasi-drug’ market. The company refers to Cytovector as an intelligent penetration technology and said it can help the delivery of active ingredients due its positive charge, which improves the ingredients’ affinity with the cell membrane.
According to BASF, it can be particularly useful for formulations aiming to fight against wrinkle formation or whitening products.
The new reformulated Cytovector, Cytovector QD, can help formulators open up the Japanese whitening market, according to BASF, where there are significant growth opportunities.
Japan holds big potential for skin whitening
Skin whitening and brightening products find their main market in Japan, China and South Korea, and to a lesser extent India.
However, the sector is expanding with ingredients being formulated into a number of anti-aging products in the attempt to reduce the appearance of age spots and irregular pigmentation which can be associated with aging skin.
Cosmetochem launch novel Liposome Herbasec® range
Liposome Herbasec® is a novel range of standardized, liposomal-based botanical extracts in powder form. In Japan, skin whitening products come under the quasi drug regulation, which means their ingredients must be compliant with the Japanese Standard of Quasi-Drug Ingredients (JSQI) which is controlled by the Ministry of Health and Labor.
In order to fit the JSQI regulations, BASF had to remove one of the ingredients, the quaternized soy protein, and replace it with an ingredient listed with the JSQI of similar efficacy, BASF spokesperson Olivier Teillac explained.
In addition, Teillac explained that the encapsulated active ingredients associated with Cytovector QD must also be QD compliant with the JSQI if they are to be suitable for the Japanese market.
New Drugs Discovered to Fight Deadly Parasite
Scientists have discovered new drugs against a parasite that infects 50,000 to 70,000 people annually in Sub-Saharan Africa. About 30,000 of those infected die. A person gets it from being bitten by a tsetse (Tet-see) fly infected with the parasite. It causes human African trypanosomiasis (HAT) and can go the individual’s brain and disturb his or her sleep cycle. The disease is often referred to as Sleeping Sickness.
There are two drugs currently available. Melarsoprol is potentially fatal to the person being treated and eflornithine is expensive and requires staying in the hospital for a long time and the parasite is becoming resistance to it.
Most individuals who are infected are poor and cannot afford to be treated. In turn, pharmaceutical companies have little to no incentive to research and develop new drugs. This discovery was made by researchers at universities in Australia and Toronto.
Researchers are working on narrowing down the list to the drug or drugs, all taken by mouth, that can best treat the disease.
Researchers Aim To Speed Cancer Drug Development By Testing On Humans, Mice In Tandem.
The Boston Globe reported that "in the new work, funded with a $4.2 million economic stimulus grant from the National Cancer Institute, mice are receiving treatment in tandem with humans...to speed up and streamline the development of cancer drugs." Cheryl Marks, associate director in the division of cancer biology at the NCI, noted that "there are 800-plus drugs in the pharmaceutical pipeline, and we already don't have enough people going into clinical trials to begin with." But, because "mice can be engineered to carry one or more faulty genes known to cause human cancers," researchers are now inserting "various human prostate- and lung-cancer gene mutations...into mice," with the hope that "the mice, with simpler genetics than the humans, will reveal more about what is happening in the patients."
http://www.pharm-education.com/2010/04/technology-designed-to-help-deliver.html
Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
Http://www.drshrutibhat.com
Expert at leading Pharmaceutical R&D.
Translates innovative concepts to PROFITS.
TouTube Channel : Http://www.youtube.com/user/ShrutiBhat10
Do you have questions for the author?
